Scholarlink

<p><i>Artemisia absinthium</i> is a perennial shrub, traditionally used for the treatment of urinary problems, anaemia, constipation, and wound healing. It is also a primary constituent of <i>Afsantein</i>, a Unani formulation. The current research is focused on the add-on therapy-based drug for the treatment of infections caused by bacterial pathogens. The hydroalcoholic extract was prepared by hot continuous method, and characterization of phytoconstituents was done by using LCMS. Identified phytoconstituents were screened for molecular docking and toxicity predictions. Bioassay-guided fractionation was done to identify the bioactive constituents, the antibacterial synergistic potential of crude extract, and its subfractions. Extractive yield of various extracts were as follows hydroalcoholic extract 15.36 ± 0.179%; n-hexane fraction 13.83 ± 0.35%; chloroform fraction 5.5 ± 0.5%; ethyl-acetate subfraction 11.2 ± 0.36%; and remaining aqueous fraction 39.49 ± 1.25%. LCMS analysis revealed four major phytoconstituents (deoxyartennium, artenetin, absinthin, and 4-caffeolyquinic acid) were identified. All the identified phytoconstituents showed comparative antibacterial activity with antibiotics and followed the drug-likeness properties. Crude extracts &amp; chloroform fraction showed the best antibacterial activities against MRSA, <i>S. aureus</i>, and <i>P. aeruginosa</i> with a zone of inhibition range of 9.33 ± 0.577 and 17.66 ± 0.57&#xa0;mm and minimum inhibitory concentration range of 128 to 512&#xa0;µg/ml. Crude extract and chloroform fraction showed synergistic activity against <i>Pseudomonas aeruginosa</i> with FICI 0.5. In a crude hydroalcoholic extract of <i>A. absinthium</i> four antibacterial phytoconstituents were identified and validated with a molecular docking study. Crude extract and chloroform fractions can be used further in antibacterial drug development against <i>Pseudomonas aeruginosa.</i></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synergistic antibacterial activity of Artemisia absinthium L. hydroalcoholic extract and sub-fractions

  • 期刊论文

  • 发表日期：

    2025年7月9日

查看全文
  • Rajan Rolta,
  • Deeksha Salaria,
  • Ajay Prakash,
  • Uma Ranjan Lal,
  • Arunanshu Behera,
  • Vikas Gautam,
  • Lileswar Kaman,
  • Bikash Medhi

摘要

Artemisia absinthium is a perennial shrub, traditionally used for the treatment of urinary problems, anaemia, constipation, and wound healing. It is also a primary constituent of Afsantein, a Unani formulation. The current research is focused on the add-on therapy-based drug for the treatment of infections caused by bacterial pathogens. The hydroalcoholic extract was prepared by hot continuous method, and characterization of phytoconstituents was done by using LCMS. Identified phytoconstituents were screened for molecular docking and toxicity predictions. Bioassay-guided fractionation was done to identify the bioactive constituents, the antibacterial synergistic potential of crude extract, and its subfractions. Extractive yield of various extracts were as follows hydroalcoholic extract 15.36 ± 0.179%; n-hexane fraction 13.83 ± 0.35%; chloroform fraction 5.5 ± 0.5%; ethyl-acetate subfraction 11.2 ± 0.36%; and remaining aqueous fraction 39.49 ± 1.25%. LCMS analysis revealed four major phytoconstituents (deoxyartennium, artenetin, absinthin, and 4-caffeolyquinic acid) were identified. All the identified phytoconstituents showed comparative antibacterial activity with antibiotics and followed the drug-likeness properties. Crude extracts & chloroform fraction showed the best antibacterial activities against MRSA, S. aureus, and P. aeruginosa with a zone of inhibition range of 9.33 ± 0.577 and 17.66 ± 0.57 mm and minimum inhibitory concentration range of 128 to 512 µg/ml. Crude extract and chloroform fraction showed synergistic activity against Pseudomonas aeruginosa with FICI 0.5. In a crude hydroalcoholic extract of A. absinthium four antibacterial phytoconstituents were identified and validated with a molecular docking study. Crude extract and chloroform fractions can be used further in antibacterial drug development against Pseudomonas aeruginosa.